{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:58:25Z","timestamp":1784206705912,"version":"3.55.0"},"reference-count":22,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,1,25]]},"DOI":"10.1253\/circj.cj-18-0874","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T22:32:15Z","timestamp":1547159535000},"page":"327-333","source":"Crossref","is-referenced-by-count":8,"title":["Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation\u3000\u2015 Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial \u2015"],"prefix":"10.1253","volume":"83","author":[{"given":"Junya","family":"Ako","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kozuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Teikyo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Morino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Iwate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Medicine Division, Nippon Boehringer Ingelheim Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Fukaya","sequence":"additional","affiliation":[{"name":"Medicine Division, Nippon Boehringer Ingelheim Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RE-DUAL PCI Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Boden WE, O\u2019Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. <i>N Engl J Med<\/i> 2007; 356: 1503\u20131516.","DOI":"10.1056\/NEJMoa070829"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Goto K, Nakai K, Shizuta S, Morimoto T, Shiomi H, Natsuaki M, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Am J Cardiol<\/i> 2014; 114: 70\u201378.","DOI":"10.1016\/j.amjcard.2014.03.060"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. <i>Circ J<\/i> 2014; 78: 1997\u20132021.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation<\/i> 2014; 130: 2071\u20132104.","DOI":"10.1161\/CIR.0000000000000040"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). <i>Eur Heart J<\/i> 2014; 35: 3155\u20133179.","DOI":"10.1093\/eurheartj\/ehu298"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kodani E, Atarashi H. Prevalence of atrial fibrillation in Asia and the world. <i>J Arrhythmia<\/i> 2012; 28: 330\u2013337.","DOI":"10.1016\/j.joa.2012.07.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. <i>Nat Rev Cardiol<\/i> 2014; 11: 639\u2013654.","DOI":"10.1038\/nrcardio.2014.118"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dewilde WJ, Janssen PW, Verheugt FW, Storey RF, Adriaenssens T, Hansen ML, et al. Triple therapy for atrial fibrillation and percutaneous coronary intervention: A contemporary review. <i>J Am Coll Cardiol<\/i> 2014; 64: 1270\u20131280.","DOI":"10.1016\/j.jacc.2014.06.1193"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Eur Heart J<\/i> 2016; 37: 2893\u20132962.","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Andrade JG, Deyell MW, Khoo C, Lee M, Humphries K, Cairns JA. Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: A systematic review and meta-analysis. <i>Can J Cardiol<\/i> 2013; 29: 204\u2013212.","DOI":"10.1016\/j.cjca.2012.06.012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hess CN, Peterson ED, Peng SA, de Lemos JA, Fosbol EL, Thomas L, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. <i>J Am Coll Cardiol<\/i> 2015; 66: 616\u2013627.","DOI":"10.1016\/j.jacc.2015.05.062"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. <i>J Am Coll Cardiol<\/i> 2013; 62: 981\u2013989.","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. <i>Circulation<\/i> 2012; 126: 1185\u20131193.","DOI":"10.1161\/CIRCULATIONAHA.112.114967"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lemesle G, Ducrocq G, Elbez Y, Van Belle E, Goto S, Cannon CP, et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <i>Clin Cardiol<\/i> 2017; 40: 932\u2013939.","DOI":"10.1002\/clc.22750"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Vardi M, Debidda M, Bhatt DL, Mauri L, Cannon CP. Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: Results from a survey among US cardiologists. <i>Clin Cardiol<\/i> 2014; 37: 103\u2013107.","DOI":"10.1002\/clc.22226"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2017; 377: 1513\u20131524.","DOI":"10.1056\/NEJMoa1708454"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>J Thromb Haemost<\/i> 2005; 3: 692\u2013694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. <i>Circulation<\/i> 2011; 123: 2363\u20132372.","DOI":"10.1161\/CIRCULATIONAHA.110.004747"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. <i>J Am Coll Cardiol<\/i> 2011; 57: 173\u2013180.","DOI":"10.1016\/j.jacc.2010.09.024"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: A North American perspective-2016 update. <i>Circ Cardiovasc Interv<\/i> 2016; 9: e004395.","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>Eur J Cardiothorac Surg<\/i> 2017; 53: 34\u201378.","DOI":"10.1093\/ejcts\/ezx334"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Eur Heart J<\/i> 2018; 39: 1330\u20131393.","DOI":"10.1093\/eurheartj\/ehy136"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/2\/83_CJ-18-0874\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T03:25:22Z","timestamp":1573701922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/2\/83_CJ-18-0874\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-18-0874","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]}}}